Protocol Number: A35-004 - Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

Project: Research project

Project Details

Effective start/end date1/12/221/12/25


  • Julius Clinical Research B.V (Prot# A35-004 // Prot# A35-004)
  • Amylyx Pharmaceuticals, Inc. (Prot# A35-004 // Prot# A35-004)